|
CheckMate 384: Phase IIIb/IV trial of nivolumab (nivo) 480 mg Q4W versus 240 mg Q2W after ≤ 12 months of nivo in previously treated advanced NSCLC. |
|
|
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Dynavax Technologies (Inst); Genentech (Inst); Iovance Biotherapeutics (Inst); Lilly (Inst); Merck (Inst); Mirati Therapeutics (Inst); Novartis (Inst) |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Lilly; Roche |
Speakers' Bureau - Bristol-Myers Squibb; Lilly; Pfizer; Roche |
Travel, Accommodations, Expenses - Boehringer Ingelheim; Lilly; MSD; Pfizer; Roche |
|
|
No Relationships to Disclose |
|
|
Stock and Other Ownership Interests - Amneal Pharmaceuticals; AstraZeneca; Bristol-Myers Squibb; Merck; Novo Nordisk; Pfizer |
Research Funding - AstraZeneca; Bristol-Myers Squibb |
|
|
Consulting or Advisory Role - Bristol-Myers Squibb |
Research Funding - Aeglea Biotherapeutics; Amgen; Bristol-Myers Squibb; Celgene; Clovis Oncology; Eisai; Genentech; GOG Foundation; Incyte; Janssen; Lilly; Merck; Novartis; Odonate Therapeutics |
|
|
Consulting or Advisory Role - Boehringer Ingelheim; Bristol-Myers Squibb |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Janssen; Roche; Sanofi |
Speakers' Bureau - Astellas Pharma; Bristol-Myers Squibb; Janssen; Roche; Sanofi |
|
|
No Relationships to Disclose |
|
|
Honoraria - AstraZeneca; Merck; Roche |
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Merck; MSD; Pfizer; Roche |
Travel, Accommodations, Expenses - AstraZeneca; Bristol-Myers Squibb; Roche |
|
|
Consulting or Advisory Role - Bristol-Myers Squibb |
|
|
Stock and Other Ownership Interests - CARP Pharmaceuticals |
Honoraria - AZD; Boehringer Ingelheim; Bristol-Myers Squibb; Lilly; MSD; Novartis; Pfizer; Roche; Teva |
Consulting or Advisory Role - AZD; Boehringer Ingelheim; Bristol-Myers Squibb; Lilly; MSD; Novartis; Pfizer; Roche; Teva |
Speakers' Bureau - AZD; Boehringer Ingelheim; Bristol-Myers Squibb; MSD; Novartis; Pfizer; Roche |
Patents, Royalties, Other Intellectual Property - Queensland University of Technology, Brisbane, Australia; Trinity College, Dublin, Ireland |
Travel, Accommodations, Expenses - AZD; Boehringer Ingelheim; Bristol-Myers Squibb; MSD; Pfizer; Roche |
|
|
Consulting or Advisory Role - AstraZeneca; Merck |
Travel, Accommodations, Expenses - AstraZeneca |
|
|
|
Consulting or Advisory Role - Boehringer Ingelheim; Merck; pfizer |
Research Funding - Abbvie (Inst); Bristol-Myers Squibb (Inst) |
|
|
Research Funding - Bristol-Myers Squibb |
|
|
Employment - Bristol-Myers Squibb |
|
|
Employment - Bristol-Myers Squibb; Bristol-Myers Squibb (I); Viant Medical; Viant Medical (I); Worldwide Clinical Trials; Worldwide Clinical Trials (I) |
Stock and Other Ownership Interests - Bristol-Myers Squibb; Bristol-Myers Squibb (I); Datascope; Datascope (I); GlaxoSmithKline; GlaxoSmithKline (I); Pfizer; Pfizer (I); Thomas Medical; Thomas Medical (I); Viant Medical; Viant Medical (I) |
Patents, Royalties, Other Intellectual Property - US National Institutes of Health; Wyeth/Pfizer |
|
|
Consulting or Advisory Role - Bristol-Myers Squibb |
Travel, Accommodations, Expenses - AstraZeneca; Bristol-Myers Squibb; Merck Serono; Pfizer |